Logo

Ascentage Pharma Entered into a Clinical Collaboration with Clover to Evaluate APG-1387 + SCB-313 for the Treatment of Peritoneal Carcinomatosis

Share this

Ascentage Pharma Entered into a Clinical Collaboration with Clover to Evaluate APG-1387 + SCB-313 for the Treatment of Peritoneal Carcinomatosis

Shots:

  • The companies collaborated to evaluate the safety, tolerability, PK/PD & efficacy of Ascentage’s APG-1387 + Clover's SCB-313 in a P-Ib/II study in patients with advanced peritoneal carcinomatosis
  • The companies are expected that a combination of SCB-313 & APG-1387 will provide a synergistic benefit to patients. Ascentage is currently conducting multiple clinical studies of APG-1387 combinations for solid tumors in China & the US.
  • Clover is planning to advance SCB-313 into a P-II trial for malignant ascites in H1’22, based on P-I interim analyses & also start P-I trials of SCB-313 for bladder cancer in 2022. APG-1387 is being evaluated in a P-II study for chronic HBV infections in China

 Ref: Businesswire| Image: Ascentage 

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions